↓ Skip to main content

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma

Overview of attention for article published in BMC Cancer, January 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
7 X users
facebook
3 Facebook pages

Citations

dimensions_citation
85 Dimensions

Readers on

mendeley
166 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
Published in
BMC Cancer, January 2017
DOI 10.1186/s12885-016-3037-z
Pubmed ID
Authors

Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture). Of the patients, 98 out of 104 completed the treatment and follow-ups. There were 49 patients in each group. The evaluating parameters included the visual analogue scale (VAS) pain score, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire scores, and electromyographic (EMG) nerve conduction velocity (NCV) determinations. We evaluated the changes of the parameters in each group before and after the therapies and made a comparison between the two groups. After 84 days (three cycles) of therapy, the pain was significantly alleviated in both groups, with a significantly higher decrease in the acupuncture treated group (P < 0.01). The patients' daily activity evaluated by Fact/GOG-Ntx questionnaires significantly improved in the Met + Acu group (P < 0.001). The NCV in the Met + Acu group improved significantly while amelioration in the control group was not observed. The present study suggests that acupuncture combined with methylcobalamin in the treatment of CIPN showed a better outcome than methylcobalamin administration alone. China Clinical Trials Register (registration no. ChiCTR-INR-16009079 , registration date August 24, 2016).

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 166 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 166 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 25 15%
Student > Master 17 10%
Other 16 10%
Student > Postgraduate 10 6%
Student > Doctoral Student 9 5%
Other 28 17%
Unknown 61 37%
Readers by discipline Count As %
Medicine and Dentistry 50 30%
Nursing and Health Professions 30 18%
Psychology 5 3%
Pharmacology, Toxicology and Pharmaceutical Science 4 2%
Engineering 3 2%
Other 10 6%
Unknown 64 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2018.
All research outputs
#6,782,242
of 23,881,329 outputs
Outputs from BMC Cancer
#1,722
of 8,483 outputs
Outputs of similar age
#124,018
of 425,820 outputs
Outputs of similar age from BMC Cancer
#34
of 105 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 8,483 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.